News
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board.
PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare
FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies.
PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017’s
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product
Gene Therapy of Liver Diseases
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases.
EMA News
This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use in the European Union (EU)
FDA news : Cellular & Gene Therapy Guidances
A useful resource of Cellular & Gene Therapy Guidance Documents
Vivet Therapeutics raises €37.5 million in Series A financing round
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
